Antibodies for prevention and treatment of respiratory syncytial virus infections in children.

Abstract	Respiratory syncytial virus (RSV) infection causes respiratory illness in all ages, and is the leading cause of hospitalizations of infants and children around the world. Those at increased risk for severe disease include infants with congenital heart disease, premature infants, children with neuromuscular disease, airway abnormalities, underlying immunodeficiencies and the elderly. Attempts to develop a safe and effective vaccine have been unsuccessful thus far. However, significant progress has been achieved in the field of passive immunoprophylaxis for protection against RSV. This review will concentrate on the past, present and future history of RSV immunoprophylaxis with an emphasis on the role of polyclonal and monoclonal antibodies.
Authors	Bessey Geevarghese, Eric A F Simões
Journal	Antiviral therapy (Antivir Ther) Vol. 17 Issue 1 Pt B Pg. 201-11 ( 2012) ISSN: 2040-2058 [Electronic] England
PMID	22311607 (Publication Type: Journal Article, Review)
Chemical References	Antibodies, Monoclonal Antibodies, Viral
Topics	Antibodies, Monoclonal (therapeutic use) Antibodies, Viral (therapeutic use) Child Humans Immunotherapy Infant Respiratory Syncytial Virus Infections (immunology, prevention & control, therapy) Respiratory Syncytial Viruses Risk Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!